|Articles|May 6, 2010
Avastin/Lucentis controversy continues
"Why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?? so asked Irv Arons in his blog spot.
Advertisement
“As I read the news release from the NEI/NIH yesterday morning, about the one-year results of the clinical trial evaluating the combination use of Lucentis with pan-retinal laser therapy to treat diabetic macular oedema, prior to posting it online, and later, when I read the complete study as posted in Ophthalmology, the one thought that kept running through my mind was, why was Lucentis, at $2000 per dose chosen for the study, rather than Avastin at $50 per dose?” so said Irv Arons in his blog spot.
What do you think? Tell us at
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
Port Delivery System Therapies in Retinal Vascular Diseases
5